2026-2034年全球慢性阻塞性肺病和气喘治疗设备市场规模、份额、趋势和成长分析报告

预计到 2034 年，慢性阻塞性肺病和气喘医疗设备市场规模将从 2025 年的 472 亿美元达到 713.1 亿美元，并预计从 2026 年到 2034 年将以 4.69% 的复合年增长率增长。

受全球呼吸系统疾病盛行率不断上升的推动，慢性阻塞性肺病（COPD）和气喘治疗设备的全球市场正经历强劲成长。吸入器、雾化器和呼吸监测设备等设备在慢性呼吸系统疾病的管理中发挥着至关重要的作用。日益严重的空气污染、吸烟习惯和环境因素导致呼吸系统疾病患者人数不断增加。医疗专业人员正越来越多地采用先进的呼吸设备来改善患者治疗和疾病管理。

慢性阻塞性肺病（COPD）和气喘在成人和儿童中的日益加重负担推动了市场成长。吸入治疗设备的科技进步提高了药物传输效率，也提升了患者的便利性。携带式、易用型设备越来越受欢迎，因为患者希望在医疗机构之外也能有效控制症状。此外，人们健康意识的提高和早期诊断项目的推广也促进了呼吸治疗设备的普及。

鑑于医疗创新推动呼吸系统照护的持续进步，慢性阻塞性肺病（COPD）和气喘治疗设备市场前景依然光明。智慧吸入器和数位化监测系统有望实现更有效的疾病追踪和治疗依从性。远端医疗和远端患者监护的普及将进一步提升患者管理水准。随着医疗系统致力于改善呼吸系统疾病的治疗效果，对先进的COPD和气喘治疗设备的需求预计将会成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球慢性阻塞性肺病和气喘治疗设备市场：依产品划分

• 市场分析、洞察与预测
• 吸入器
• 喷雾器

第五章 全球慢性阻塞性肺病和气喘治疗设备市场：依适应症划分

• 市场分析、洞察与预测
• 气喘
• COPD

第六章 全球慢性阻塞性肺病和气喘治疗设备市场：依通路划分

• 市场分析、洞察与预测
• 零售药房
• 医院
• 网路药房

第七章 全球慢性阻塞性肺病和气喘治疗设备市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • GF Health Products Inc
  • Koninklijke Philips NV（Philips）
  • 3M Company
  • Boehringer Ingelheim International GmbH
  • PARI Medical Holding GMBH
  • AstraZeneca PLC
  • Smith's Group Plc
  • Aerogen Inc
  • Baxter International Inc
  • GlaxoSmithKline Plc
  • Novartis AG

The COPD and Asthma Devices Market size is expected to reach USD 71.31 Billion in 2034 from USD 47.20 Billion (2025) growing at a CAGR of 4.69% during 2026-2034.

The global COPD and asthma devices market has witnessed strong growth due to the increasing prevalence of respiratory diseases worldwide. Devices such as inhalers, nebulizers, and respiratory monitoring equipment play a crucial role in managing chronic respiratory conditions. Rising air pollution levels, smoking habits, and environmental factors have contributed to the growing number of individuals diagnosed with respiratory disorders. Healthcare providers are increasingly adopting advanced respiratory devices to improve patient treatment and disease management.

Market growth is driven by the rising burden of chronic obstructive pulmonary disease and asthma among both adults and children. Technological advancements in inhalation therapy devices have improved medication delivery and patient convenience. Portable and user-friendly devices are becoming more popular as patients seek effective ways to manage symptoms outside clinical settings. Increasing healthcare awareness and early diagnosis programs have also contributed to higher adoption of respiratory treatment devices.

The future outlook for the COPD and asthma devices market remains positive as healthcare innovation continues to improve respiratory care. Smart inhalers and digital monitoring systems may enable better disease tracking and treatment adherence. Expansion of telemedicine and remote patient monitoring could further enhance patient management. As healthcare systems focus on improving respiratory disease outcomes, demand for advanced COPD and asthma treatment devices is expected to rise.

MARKET SEGMENTATION

By Product

• Inhalers
• Nebulizers

By Indication

• Asthma
• COPD

By Distribution Channel

• Retail Pharmacies
• Hospitals
• Online Pharmacies

COMPANIES PROFILED

• GF Health Products Inc, Koninklijke Philips NV Philips, 3M Company, Boehringer Ingelheim International GmbH, PARI medical Holding GMBH, AstraZeneca PLC, Smiths Group Plc, Aerogen Inc, Baxter International Inc, GlaxoSmithKline Plc, Novartis AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL COPD AND ASTHMA DEVICES MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Inhalers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Nebulizers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL COPD AND ASTHMA DEVICES MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Asthma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. COPD Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL COPD AND ASTHMA DEVICES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL COPD AND ASTHMA DEVICES MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Indication
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Indication
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Indication
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Indication
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Indication
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL COPD AND ASTHMA DEVICES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 GF Health Products Inc
  • 9.2.2 Koninklijke Philips N.V. (Philips)
  • 9.2.3 3M Company
  • 9.2.4 Boehringer Ingelheim International GmbH
  • 9.2.5 PARI Medical Holding GMBH
  • 9.2.6 AstraZeneca PLC
  • 9.2.7 Smith's Group Plc
  • 9.2.8 Aerogen Inc
  • 9.2.9 Baxter International Inc
  • 9.2.10 GlaxoSmithKline Plc
  • 9.2.11 Novartis AG